In collaborative research led by The Pirbright Institute, scientists have generated a ‘hybrid’ foot-and-mouth disease virus (FMDV) with improved stability, which will increase its effectiveness when administered as a vaccine. They targeted the Southern African Territories (SAT) 2 serotype viruses, which are among the least stable of the seven different types of FMDV.
Under the leadership of Pirbright’s Dr Elma Tchilian the Comparative and Veterinary Immunology Group (CVIG) has been revived and is actively engaging in opportunities to showcase the research of its members and bring knowledge of comparative and veterinary immunology to a wider audience.
Scientists from The Pirbright Institute’s Vaccine Differentiation group have recently returned from Chennai in India, where they conducted a mass peste des petits ruminants (PPR) vaccination campaign and awareness programme. They joined scientists from four specialist organisations; Tamil Nadu Veterinary and Animal Sciences University (TANUVAS), Indian Veterinary Research Institute (IVRI), National Institute of Animal Biotechnology (NIAB) and National Institute of Veterinary Epidemiology and Disease Informatics (NIVEDI).